TITLE

Dose–Risk and Duration–Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies

AUTHOR(S)
Ye, Xiaohua; Fu, Jinjian; Yang, Yi; Chen, Sidong
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In previous meta-analyses, aspirin use has been associated with reduced risk of colorectal cancer. However, uncertainty remains on the exact dose–risk and duration–risk relationships. Methods: We identified studies by searching several English and Chinese electronic databases and reviewing relevant articles. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Subgroup analyses were conducted to explore possible heterogeneity among studies. Potential heterogeneity was calculated as Q statistic and I2 value. Publication bias was evaluated using funnel plots and quantified by the Begg’s and Egger’s test. Results: Twelve studies were included in this meta-analysis. An inverse association between aspirin use and colorectal cancer was observed in both the overall group (RR = 0.74, 95% CI 0.64–0.83 for aspirin dose; RR = 0.80, 95% CI 0.75–0.85 for frequency of aspirin use; RR = 0.75, 95% CI 0.68–0.81 for years of aspirin use) and subgroups stratified by sex and cancer site. The dose-response meta-analysis showed that there was a 20% statistically significant decreased risk of colorectal cancer for 325 mg aspirin per day increment, 18% decreased risk for 7 times aspirin per week increment and 18% decreased risk for 10 years aspirin increment. Conclusion: Long-term (>5 years), low-dose (75–325 mg per day) and regular aspirin use (2–7 times per week) can effectively reduce the risk of colorectal cancer.
ACCESSION #
87625548

 

Related Articles

  • Evidenzlage der laparoskopischen Chirurgie beim Rektumkarzinom. Fürst, A.; Heiligensetzer, A.; Sauer, P.; Liebig-Hörl, G. // Der Chirurg;Jul2014, Vol. 85 Issue 7, p578 

    Background: Innovative surgical techniques in colorectal surgery aim to provide diminished surgical injury and at least equivalent or even improved quality of treatment and oncological results. High level clinical studies are mandatory to examine the feasibility and advantages (or disadvantages)...

  • Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis. Veronese, N.; Nottegar, A.; Pea, A.; Solmi, M.; Stubbs, B.; Capelli, P.; Sergi, G.; Manzato, E.; Fassan, M.; Wood, L. D.; Scarpa, A.; Luchini, C. // Annals of Oncology;Jan2016, Vol. 27 Issue 1, p42 

    Background: The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM)...

  • Screening before providing cetuximab cost saving.  // PharmacoEconomics & Outcomes News;1/12/2013, Issue 669, p6 

    The article discusses research being done on the use of cetuximab in patients with metastatic colorectal Cancer (mCRC), referencing the study "Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer," by A. S. Behl et al. published in the November 28,...

  • Behind the Stethoscope. BENNETT, JEANETTE // Utah Valley Magazine;Jan/Feb2014, Vol. 15 Issue 1, p80 

    The article discusses miscellaneous issues including how basketball player Wes Bell survived from the stage three colon and rectal cancer, free services offered by the Community Health Connect and research conducted by doctor Helen Feltovich. As mentioned, research of Feltovich has been funded...

  • CONFERENCE PAPERS.  // Archive of Oncology;2009 Supplement 2, Vol. 17, p9 

    The article discusses several studies including the new drugs for the treatment of metastatic colorectal cancer, the combination of chemoradiation with cytotoxic agents in preoperative treatment of locally advanced rectal cancer, and the treatment for peritoneal carcinomatosis. An overview of...

  • Effects of Topical Tumoricidal Agents on Port-Site Recurrence of Colon Cancer: An Experimental Study in Rats. Hoffstetter, Wayne; Ortega, Adrian; Chiang, Mimi; Paik, Peter; Beart, Robert W. // Journal of Laparoendoscopic & Advanced Surgical Techniques;Feb2001, Vol. 11 Issue 1, p9 

    Background: Reports of metastatic spread of colon and rectal cancer to port sites after laparoscopic resection of potentially curable lesions has raised doubt regarding the efficacy and safety of laparoscopic technology in cancer surgery. Experimental study in animals has led us to believe that...

  • Rectal Site and Suboptimal Nodal Yield Predict Systemic Recurrence in Resected Colorectal Carcinoma: A Case-Control Study. Hayes, Brian D.; O’Riordan, James M.; Stuart, Charlotte; Muldoon, Cian // International Journal of Surgical Pathology;Sep2014, Vol. 22 Issue 6, p505 

    We assessed the contribution of histopathological features to systemic recurrence (SR) in patients with colorectal cancer, using a case-control design: 71 cases and 184 controls were included, with a mean time until SR of 1.4 ± 0.1 years and a mean follow-up of controls of 1.6 ± 0.06...

  • ABC of colorectal cancer: Treatment of advanced disease. Young, Annie; Rea, Daniel // BMJ: British Medical Journal (International Edition);11/18/2000, Vol. 321 Issue 7271, p1278 

    Provides information on the treatment of colorectal cancer in its advanced stages. Symptoms of colorectal cancer; Small percentage of colorectal cancer patients that are referred to medical oncologists; Benefits of chemotherapy for colorectal cancer patients including improved quality of life;...

  • MABEL: cetuximab plus irinotecan safe, effective for metastatic colorectal cancer.  // Hem/Onc Today;11/25/2008, Vol. 9 Issue 21, p38 

    The article discusses research being done on the therapeutic effectiveness of the combined regimen of cetuximab and irinotecan for patients with epidermal growth factor-expressing metastatic colorectal cancer who failed prior irinotecan treatment. The study, published in the 2008 issue of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics